Loading...
XNASATHE
Market cap11bUSD
Dec 20, Last price  
2.20USD
1D
4.76%
1Q
78.86%
Jan 2017
34.97%
Name

Alterity Therapeutics Ltd

Chart & Performance

D1W1MN
XNAS:ATHE chart
P/E
—
P/S
7,184.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-21.66%
Revenues
4m
+2.63%
2,642,335762,486507,044491,997428,193215,008156,135186,664150,867363,775176,842142,657132,396201,174108,538411,5673,254,0483,537,3683,916,3334,019,285
Net income
-19m
L+38.51%
0000-7,522,789-4,906,922-6,431,185-5,239,469-7,787,242-13,329,239-5,885,069-7,729,551-7,542,076-8,265,737-12,337,830-10,059,684-15,309,353-12,847,061-13,806,515-19,123,464
CFO
-13m
L-37.08%
0000-6,994,174-4,708,939-4,558,415-6,845,906-7,951,254-13,788,974-10,871,074-7,418,526-5,865,080-6,245,188-13,954,818-9,431,122-17,330,069-12,337,274-20,035,837-12,605,824
Earnings
Feb 03, 2025

Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
URL
https://alteritytherapeutics.com/
IPO date
Mar 28, 2000
Employees
11
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
4,019
2.63%
3,916
10.71%
3,537
8.71%
Cost of revenue
23,621
18,523
20,457
Unusual Expense (Income)
NOPBT
(19,602)
(14,607)
(16,920)
NOPBT Margin
Operating Taxes
46
104
70
Tax Rate
NOPAT
(19,648)
(14,711)
(16,990)
Net income
(19,123)
38.51%
(13,807)
7.47%
(12,847)
-16.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,145
317
17,176
BB yield
Debt
Debt current
107
107
58
Long-term debt
211
206
177
Deferred revenue
Other long-term liabilities
20
14
Net debt
(12,321)
(15,460)
(34,572)
Cash flow
Cash from operating activities
(12,606)
(20,036)
(12,337)
CAPEX
(6)
(7)
(89)
Cash from investing activities
(6)
(36)
(89)
Cash from financing activities
9,216
124
16,561
FCF
(13,578)
(21,322)
(15,353)
Balance
Cash
12,639
15,774
34,807
Long term investments
Excess cash
12,438
15,578
34,630
Stockholders' equity
8,992
22,813
35,469
Invested Capital
4,965
7,572
943
ROIC
ROCE
EV
Common stock shares outstanding
6,081
4,046
2,405,990
Price
Market cap
EV
EBITDA
(19,454)
(14,504)
(16,866)
EV/EBITDA
Interest
Interest/NOPBT